


VITEK® REVEAL™

GRAM-NEGATIVE (GN01-AST) PANEL



Wide antimicrobial coverage for Gram-negative bloodstream infections, with 176 bug drug combinations.



ANTIMICROBIAL DRUG	MIC CALLING RANGE (µg/ml)												
		A. baumannii	C. freundii	C. koseri	E. cloacae	E. coli	K. aerogenes	K. oxytoca	K. pneumoniae	P. mirabilis	P. aeruginosa		
Amikacin	4 - 16	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	10
Amoxicillin / Clavulanate	4/2 - 16/2			✓		✓		✓	✓	✓			5
Ampicillin	4 - 8					✓					✓		2
Aztreonam	1 - 16	✓	✓	✓	✓	✓	✓	✓			✓		8
Cefepime	0.125 - 64	✓	✓	✓	✓			✓	✓	✓	✓		8
Cefotaxime	0.125 - 4	✓	✓	✓	✓	✓	✓	✓	✓	✓			8
Cefoxitin	8 - 16			✓		✓		✓	✓	✓			5
Ceftazidime	0.125 - 64	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		9
Ceftazidime / Avibactam	0.25/4, 1/4 - 16/4	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ceftazidime / Clavulanate	0.25/4 - 8/4					✓		✓	✓				3
Ceftolozane / Tazobactam	1/4 - 4/4				✓	✓	✓	✓	✓	✓		✓	6
Ciprofloxacin	0.06, 0.25 - 1	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	10
Ertapenem	0.125 - 1		✓	✓	✓	✓	✓	✓	✓	✓			8
Gentamicin	2 - 4	✓	✓	✓	✓	✓	✓	✓	✓	✓			9
Imipenem	1 - 8	✓	✓	✓	✓	✓	✓	✓	✓		✓		9
Levofloxacin	0.25 - 1	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	10
Meropenem	0.125 - 8	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	10
Meropenem / Vaborbactam	2/8 - 8/8		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Piperacillin	8 - 16		✓		✓	✓	✓	✓	✓	✓	✓	✓	8
Piperacillin / Tazobactam	4/4 - 16/4		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Tigecycline	0.5 - 1			✓		✓							2
Tobramycin	2 - 4	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	10
Trimethoprim / Sulfamethoxazole	2/38 - 4/76	✓	✓	✓	✓	✓	✓	✓	✓	✓			9
TOTAL		8	17	19	18	23	17	21	21	18	14	176	

System reports results with S/I/R interpretation according to CA-SFM 2019 and EUCAST 2021 Breakpoints

NOVEL TECHNOLOGY DETERMINES MIC DIRECTLY FROM POSITIVE BLOOD CULTURE



The panel includes highly sensitive nanoporous sensors. The sensors change color in response to metabolic volatiles produced by microorganisms during growth to quantify antibiotic efficacy.



SIMPLE PREP IN <3 MINUTES




Dilute



Decant



Inoculate



Cover with Sensor Panel



Seal Assay



Run AST Panel

AVERAGE 5.5 HOURS TIME TO RESULT¹

PERFORMANCE OVERVIEW²

- ISO COMPLIANCE 20776-2:2007
- 97.9% EA and 96.7% CA with 19.1% resistant organisms
- Only 1.0% VME and 1.2% ME

Product availability varies by country. Consult your bioMérieux representative.

References

1. Clinical evaluation of the SPECIFIC REVEAL™ with Gram-negative bacteremia samples in 6 hospitals in France and England - 2021
2. As of December 2021, 867 clinical strains are tested across 7 hospitals

Manufactured by Specific Diagnostics

130 Baytech Dr. San Jose • CA 95134 • USA



bioMérieux S.A. • 69280 Marcy l'Etoile • France • Tel: +33 (0) 4 78 87 20 00 • Fax: +33 (0) 4 78 87 20 90
www.biomerieux.com